Retatrutide: What the Clinical Trial Data Shows

What Is Retatrutide?

Retatrutide (LY3437943) is a triple-agonist peptide developed by Eli Lilly that targets the GIP, GLP-1, and glucagon receptors simultaneously. It represents the next step in a progression that started with single-receptor GLP-1 agonists like semaglutide, moved to dual-receptor agonists like tirzepatide, and now adds a third signaling pathway to the mix.

The compound uses a GIP-based peptide scaffold similar to tirzepatide’s, but with amino acid modifications that confer activity at the glucagon receptor (GCGR). Like its predecessor, it includes a fatty acid moiety for albumin binding that extends its half-life to approximately six days, enabling once-weekly subcutaneous dosing.

The Phase 2 Trial: Design and Population

The pivotal Phase 2 study (Jastreboff et al., NEJM 2023) randomized 338 adults with obesity or overweight with at least one weight-related comorbidity. Participants had a mean baseline BMI of 37 kg/m2 and a mean body weight of approximately 108 kg. They were randomized across six retatrutide dose groups and one placebo group for 48 weeks.

The trial used an escalating dose design for most arms, starting participants at lower doses and titrating upward over the first 12 to 20 weeks. The 4mg and 8mg maintenance arms started at their full dose immediately, which allowed the researchers to assess the impact of titration on tolerability.

No active comparator was included. This is standard for Phase 2 dose-finding studies, where the primary goal is to identify the right doses for Phase 3, not to beat a competitor. But it does mean we cannot make direct, trial-level comparisons to tirzepatide or semaglutide.

Weight Loss Results by Dose

The dose-response relationship was steep and consistent. At 0.5mg maintenance, weight loss was modest at 3.19%. At 4mg maintenance, it reached 12.9%. At 8mg maintenance, 22.8%. And at 12mg with escalation, the top dose arm, weight loss hit 24.2%.

Perhaps the most striking observation is the weight loss trajectory. At 48 weeks, the curves in the highest dose arms were still descending. They had not plateaued. This is different from both semaglutide and tirzepatide, where weight loss typically levels off between 40 and 60 weeks. If the trajectory holds in longer studies, retatrutide’s ceiling could be higher than what the 48-week data shows.

At 48 weeks, 100% of participants on the 12mg dose had lost at least 5% of their body weight. In obesity trial history, a 100% response rate at any clinically meaningful threshold is almost unheard of.

Benchmarking Against the Current Standard

While no head-to-head trial exists, cross-trial comparisons provide useful context. Tirzepatide produced 22.5% weight loss at 15mg over 72 weeks in SURMOUNT-1. Semaglutide produced 14.9% at 2.4mg over 68 weeks in STEP 1. Retatrutide reached 24.2% in just 48 weeks at 12mg.

The Glucagon Component: Energy Expenditure

What distinguishes retatrutide from tirzepatide is the glucagon receptor agonism. GLP-1 and GIP primarily reduce energy intake. They suppress appetite, slow gastric emptying, and improve the efficiency of insulin signaling. Glucagon does something different: it increases energy expenditure.

Glucagon receptor activation in the liver triggers increased fatty acid oxidation, ketogenesis, and thermogenesis. The liver burns more fuel. In animal models, GCGR agonism has also been shown to reduce hepatic steatosis (fatty liver). This is particularly relevant because MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) is a growing target indication for incretin-based therapies.

The theoretical appeal of this three-pronged approach is straightforward. If you reduce how much energy goes in (GLP-1 appetite suppression), improve how efficiently that energy is used (GIP insulin sensitivity), and increase how much energy the body burns at rest (glucagon thermogenesis), you should get a more complete metabolic intervention than any one or two of those pathways alone. The Phase 2 data is consistent with that theory.

Safety and Tolerability

The side effect profile resembled what has been seen with other incretin-based therapies, with gastrointestinal symptoms being the most common adverse events. Nausea, diarrhea, vomiting, and constipation were all reported at rates that increased with dose.

The TRIUMPH Phase 3 Program

Eli Lilly launched the TRIUMPH Phase 3 program for retatrutide in 2023. The program includes multiple trials spanning obesity, Type 2 diabetes, and MASH. The obesity trials are expected to enroll thousands of participants across multiple doses and run for at least 72 weeks, bringing the data much closer to the scale and rigor of the SURMOUNT and STEP programs.

The critical question the Phase 3 data will answer is whether the 24.2% weight loss signal from Phase 2 holds up in a larger, more diverse population over a longer time horizon. Phase 2 results often attenuate somewhat in Phase 3, but even a modest decline from 24% would still place retatrutide at or above tirzepatide’s best published numbers.

If Phase 3 confirms even 80% of the Phase 2 effect, retatrutide would still represent the most effective anti-obesity pharmaceutical in history.

For detailed pharmacological profiles, see our research pages on retatrutide and tirzepatide. The competitive landscape between dual and triple agonists is the most active area of metabolic peptide research, and the next two years of data will determine how it resolves.

This article is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before making health-related decisions. Clinical trial data referenced here is sourced from peer-reviewed publications and may not reflect the most current findings.